title: Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
abstract: OBJECTIVE
  To investigate the diagnostic value of the nuclear matrix protein 22 (NMP-22) in residual tumors after complete transurethral resection (TUR) of bladder cancer.
  
  
  METHODS
  A total of 160 patients diagnosed with non-muscle invasive bladder cancer were prospectively enrolled in the study. Before the initial TUR, the patients were evaluated using urine cytology and the NMP-22 Bladder Chek™. After 4-6 weeks, all patients underwent a second TUR, urine cytology and NMP-22 Bladder Chek™ evaluation.
  
  
  RESULTS
  The mean patient age was 59.8 ± 1.0 years. Of the 160 patients, 81 (50.6%) had positive NMP-22 findings and 53 (33.1%) had positive urine cytology findings. In 101 (63.1%) patients, at least one marker was positive. There was no correlation between the positivity ratio of the NMP-22 and the degree of risk group (p = 0.156); however, in the high-risk group, the malignant cytology ratio was higher (p < 0.001). In 60 patients (37.5%), there were tumors in the second TUR. NMP-22 results of 40 of these patients (66.7%) were positive, and for 28 (46.7%), the cytology results were positive. The sensitivity, specificity, positive predictive value, and negative predictive value of the NMP-22 alone was 66.7, 81, 67.8, and 80.2 %, respectively; for the cytology, it was 46.7, 98, 93.3, and 75.4%, respectively; and for the NMP-22 and cytology combined, it was 73.3, 79, 67.7, and 83.2%, respectively.
  
  
  CONCLUSIONS
  NMP-22 Bladder Chek™ test has limited efficacy in detecting residual tumors before a second TUR. The combination of this test with cytology has no additional benefit.
authors: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Sihhiye, 06120, Ankara, Turkey.
authors: Melih
authors: M
authors: Balci
authors: Altug
authors: A
authors: Tuncel
authors: Ozer
authors: O
authors: Guzel
authors: Yilmaz
authors: Y
authors: Aslan
authors: Tezcan
authors: T
authors: Sezgin
authors: Ovunc
authors: O
authors: Bilgin
authors: Cagdas
authors: C
authors: Senel
authors: Ali
authors: A
authors: Atan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D002277:Carcinoma / Q000175:diagnosis* / Q000601:surgery / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D009687:Nuclear Proteins / Q000652:urine*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012086:Reoperation; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000601:surgery / Q000652:urine; D014556:Urine / Q000166:cytology; D019459:Urothelium; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22
references: Am J Surg Pathol. 1998 Dec;22(12):1435-48
references: 9850170
references: J Urol. 1999 Jul;162(1):74-6
references: 10379743
references: Urol Oncol. 2014 Apr;32(3):222-9
references: 24054865
references: J Urol. 2003 Aug;170(2 Pt 1):433-7
references: 12853793
references: Eur Urol. 2008 May;53(5):909-16
references: 18162285
references: Eur Urol. 2005 Dec;48(6):951-6; discussion 956
references: 16257108
references: Urol Clin North Am. 2013 May;40(2):165-73
references: 23540775
references: BJU Int. 2008 Jun;101(11):1362-7
references: 18284410
references: Urology. 2009 Mar;73(3):592-6; discussion 596-7
references: 19168205
references: J Urol. 2006 Apr;175(4):1258-61
references: 16515974
references: Urology. 2002 Feb;59(2):220-3
references: 11834389